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Tobacco smoking has been linked to an increased risk of multiple sclerosis. However, to date, results from the few studies on
the impact of smoking on the progression of disability are conflicting. The aim of this study was to investigate the effects of
smoking on disability progression and disease severity in a cohort of patients with clinically definite multiple sclerosis. We
analysed data from 895 patients (270 male, 625 female), mean age 49 years with mean disease duration 17 years. Forty-nine per
cent of the patients were regular smokers at the time of disease onset or at diagnosis (ever-smokers). Average disease severity
as measured by multiple sclerosis severity score was greater in ever-smokers, by 0.68 (95% confidence interval: 0.36–1.01). The
risk of reaching Expanded Disability Status Scale score milestones of 4 and 6 in ever-smokers compared to never-smokers was
1.34 (95% confidence interval: 1.12–1.60) and 1.25 (95% confidence interval: 1.02–1.51) respectively. Current smokers showed
1.64 (95% confidence interval: 1.33–2.02) and 1.49 (95% confidence interval: 1.18–1.86) times higher risk of reaching
Expanded Disability Status Scale scores 4 and 6 compared with non-smokers. Ex-smokers who stopped smoking either
before or after the onset of the disease had a significantly lower risk of reaching Expanded Disability Status Scale scores 4
(hazard ratio: 0.65, confidence interval: 0.50–0.83) and 6 (hazard ratio: 0.69, confidence interval: 0.53–0.90) than current
smokers, and there was no significant difference between ex-smokers and non-smokers in terms of time to Expanded
Disability Status Scale scores 4 or 6. Our data suggest that regular smoking is associated with more severe disease and
faster disability progression. In addition, smoking cessation, whether before or after onset of the disease, is associated with
a slower progression of disability.
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Introduction
Multiple sclerosis is a chronic inflammatory demyelinating disease
of unknown aetiology characterized by a misdirected immune
response affecting the CNS. Pathologically, multiple sclerosis is
characterized by demyelination, inflammation and axonal
damage within the brain and spinal cord. It is widely accepted
that multiple sclerosis development and progression depend on a
combination of genetic and environmental factors, which are cur-
rently incompletely known. The natural history varies widely
amongst individuals and around the world. In general, at the
disease onset an estimated 85–90% of patients have a
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relapsing-remitting clinical course that is characterized by clearly
defined relapses with full or partial recovery, whereas the remain-
ing 10–15% have primary-progressive multiple sclerosis, which
represents a relentless progression from the beginning with no
remission (Compston and Coles, 2008). Of the patients with relap-
sing-remitting multiple sclerosis, 80–90% eventually evolve to
secondary-progressive multiple sclerosis within 10 to 20 years
from onset (Weinshenker et al., 1989). The causes of transition
and the interplay of risk factors are not entirely known. The aver-
age annual cost to the National Health Service of £30 263 per
individual makes multiple sclerosis one of the most costly condi-
tions in the UK (Kobelt et al., 2006; Orme et al., 2007;
Manouchehrinia and Constantinescu, 2012). Given the fact that
multiple sclerosis is a life-long chronic disease and with estimated
prevalence rates between 84 and 203 per 100 000 population in
the UK alone (Ford et al., 1998; Rothwell and Charlton, 1998),
the impact of multiple sclerosis, in terms of the strain on health
services as well as cost, is considerable. It is therefore important to
identify means to prevent the onset, and slow the progression of
multiple sclerosis.
Smoking is an avoidable exposure that has previously been
linked with an estimated 50% increased risk of developing mul-
tiple sclerosis in case-control studies (Antonovsky et al., 1965;
Ghadirian et al., 2001; Hernan et al., 2001; Riise et al., 2003,
2011; Hawkes, 2007; Hedstrom et al., 2009, 2011; Simon
et al., 2010). However, it is not entirely clear whether smoking
also influences the clinical course of the disease, the few studies
addressing this issue having yielded conflicting results. The results
of a recent meta-analysis of these studies examining the role of
smoking in disease progression fell short of statistical significance
and showed high heterogeneity (Handel et al., 2011). The possible
correlation between smoking and disease progression in multiple
sclerosis is of particular interest in view of reports on a negative
correlation between smoking and some neurodegenerative condi-
tions (e.g. Parkinson’s disease; Checkoway et al., 2002) and some
autoimmune disorders (e.g. ulcerative colitis; Boyko et al., 1987).
The evaluation of the magnitude of the effect of cigarette smok-
ing on the clinical course of multiple sclerosis may help to deter-
mine underlying disease mechanisms and is important, as studies
have reported a high percentage of smokers amongst patients
with multiple sclerosis (Marrie et al., 2009). Here we examine
the effects of smoking on the disability progression and explore
the potential benefit of smoking cessation using data from a well-




The study population comprised patients registered in the largest East
Midlands multiple sclerosis specialist clinic database at Nottingham
University Hospital, which contains 498% of the identified patients
with multiple sclerosis in Nottinghamshire and certain parts of
Lincolnshire and Derbyshire. Patients in this registry must have the
diagnosis of multiple sclerosis, clinically isolated syndrome or suspected
multiple sclerosis. As the major NHS referral centre in East Midlands,
the multiple sclerosis specialist clinic covers the region’s multiple scler-
osis population and provides access to therapy. All the clinically def-
inite multiple sclerosis diagnoses in our cohort are supported by a
positive result of a MRI scan and made by a multiple sclerosis specialist
neurologist. Patients are seen routinely and undergo medical and
neurological evaluation including estimation of Expanded Disability
Status Scale (EDSS) score (Kurtzke, 1983), with reporting of history,
treatments and investigation results. Of all the patients registered in
the clinic, 1126 patients were registered on the clinical database cre-
ated by one multiple sclerosis specialist neurologist (C.S.C.) with the
aim of investigating prospectively the comorbid conditions associated
with multiple sclerosis (Edwards and Constantinescu, 2004). Of these,
we were unable to review and collect data from 94 cases during the
study period. This provided 1032 cases for review with a median of 15
years of clinical data. The study was approved by the National
Research Ethics Service East Midlands Ethics Committee Derby-1.
Data used in the study
Age, gender, and duration of disease modifying treatment were ob-
tained. Disease modifying treatments were modelled as a binary vari-
able in which patients were grouped into those who received
treatment for 51 year and those who received treatment for 1 year
or more (51). Age at onset was defined as the age at the time of the
first manifestation of the disease or any neurological sign indicative of
multiple sclerosis identified by a multiple sclerosis specialist neurologist.
EDSS scores obtained from the neurologist’s report were used in the
analysis. The type of clinical course at the onset of the disease was also
collected and patients were classified as relapsing-remitting multiple
sclerosis or primary-progressive multiple sclerosis based on the criteria
of Lublin and Reingold (1996). Disease duration was calculated from
the date of first manifestation of the disease to the date of the last
EDSS score on record. We also calculated global Multiple Sclerosis
Severity Score (MSSS) from EDSS score and disease duration according
to the guidelines by Roxburgh et al. (2005).
Smoking history
Patients were asked about smoking status and, if they were smokers,
number of cigarette smoked per day at their first clinic visit at the time
of the first manifestation of the disease or time of diagnosis. Patients
were grouped as being non-smokers, ex-smokers or current smokers.
‘Ever-smoking’ was defined based on criteria by The European
Community Respiratory Health Survey III (Burney et al., 1994) as at
least 20 packs of cigarettes or 12 oz (360 g) of tobacco in a lifetime, or
at least one cigarette per day or one cigar a week for 1 year.
Statistical methods
Descriptive statistics were used to summarize the baseline demo-
graphic characteristics and clinical outcomes. We examined the asso-
ciation between smoking and the type of multiple sclerosis at its onset
(relapsing-remitting multiple sclerosis or primary-progressive multiple
sclerosis) using logistic regression models. Linear regression models
were used to determine the effects of smoking intensity on the sever-
ity of the disease measured by MSSS score. Detailed models were
adjusted for onset age, sex, type of multiple sclerosis at the onset of
the disease (relapsing-remitting versus primary-progressive) and use of
treatment. Although regression models of large sample size are robust
to some degree of non-normality (Lumley et al., 2002), all the linear











models were controlled for homogeneity and distribution of residuals
to avoid violation of underlying normality assumption.
Time to two EDSS milestone scores of 4 and 6 was estimated using
the Kaplan-Meier method taking into account participation of those
that have not yet reached EDSS scores 4 or 6. The smoking-specific
rate ratios were calculated using Cox proportional hazard regression
models (Cox and Oakes, 1984) controlled for sex, onset age (continu-
ous in years), use of disease modifying treatments (in a binary group
of 51 year or 51 year) and initial clinical course of the disease
(relapsing-remitting versus primary-progressive). Cox regression
models were also used to estimate the rate ratios of reaching MSSS
score categories 5 or above (patient progress faster than half of the
multiple sclerosis population) and 7.5 or above (patients progress
faster than 75% of the multiple sclerosis population) between smoking
groups. Age is one of the most important factors in accumulation of
disabilities in multiple sclerosis and the hazard will significantly change
as a function of age. To account for this, patients in the cohort were
followed from the date of birth, entered the study at the age at the
onset of the disease (left truncation or late entry) and exit at their
event/censoring age. This way the impact of age was controlled for
more effectively (Korn et al., 1997). The final Cox models were
checked for proportionality assumption based on the Schoenfeld re-
siduals and were stratified by sex and/or initial disease type to hold the
proportionality assumption. A comparison of the effects of smoking on
the likelihood of patients being in the upper quartiles (MSSS4 7.5)
versus lower quartiles (MSSS5 2.5) of the MSSS spectrum was made
using a logistic regression model to ensure the robustness of the results
when using MSSS as an outcome of interest. All statistical analyses
were performed with Stata 11 (StataCorp. 2009. Stata Statistical
Software: Release 11 StataCorp LP).
Results
Of the 1032 patients, 30 patients (12 clinically isolated syndrome
and 18 multiple sclerosis diagnosis suspected only) did not fulfil
McDonald and/or Poser criteria (Poser et al., 1983; McDonald
et al., 2001) and were therefore excluded from the study. We
were unable to collect sufficient demographic data from 33 pa-
tients. In addition, smoking data were unavailable for 74 subjects.
Thus there were 895 subjects with full data for analysis.
Comparison of our final population with the 74 patients excluded
due to missing smoking data showed that the two populations
were highly similar across all demographic and clinical outcome
variables (data not shown). Of 895 patients (270 male, 625
female) with mean standard deviation (SD) age of 49 (11) years
and mean disease duration of 17 (10) years, 49% were regular
smokers at the time of disease onset or at diagnosis.
Approximately half of the participants (49%) had relapsing-remit-
ting multiple sclerosis, 39% secondary-progressive multiple scler-
osis, and 11% primary-progressive multiple sclerosis. Sixty-eight
patients stopped smoking before the onset of the disease and
117 patients stopped smoking an average of 10 (8) years
after the disease onset. Patients who stopped smoking before dis-
ease onset were significantly older [39 (11) years] at the onset
of the disease than those who stopped after the disease onset [31
(9) years] (P50.001). In general, our cohort characteristics
were similar to those reported for the typical multiple sclerosis
population (Table 1).
Smoking, disease type and severity of
multiple sclerosis
We could not find any association between smoking status and
having progressive type of multiple sclerosis at disease onset
(relapsing-remitting multiple sclerosis versus primary-progressive
multiple sclerosis). In our cohort, after controlling for sex and
onset age, the risk of having progressive clinical course (primary-
progressive multiple sclerosis) at disease onset was independent of
smoking status (odds ratio = 0.82; P = 0.396; 95%CI: 0.52–1.29).
There were also no significant differences between the proportion
of ever-smokers in relapsing-remitting multiple sclerosis and sec-
ondary-progressive multiple sclerosis groups (chi-square with one
degree of freedom = 0.1102, P = 0.740). Male patients and those
with late onset of the disease were significantly more likely to
have progressive disease at onset. Median (interquartile range)
diagnosis lag time between onset of symptoms and diagnosis of
multiple sclerosis was 3 (6) years in never-smokers and 2 (6) years
in ever-smokers (P = 0.2).
Comparison of patients in the upper and lower quartiles of dis-
ease severity, measured by MSSS (MSSS5 2.5, n = 163; and
MSSS47.5, n = 287), showed a higher proportion of ever-smo-
kers in the upper quartiles MSSS (57% versus 35%, chi-square
with one degree of freedom = 18.76, P50.001). Using the logis-
tic regression model, we noted that ever-smokers were 2.37 times
(P5 0.001, 95%CI: 1.52 to 3.7) more likely to fall in the upper
quartile MSSS than lower quartile compared with never-smokers.
Median times to MSSS score category 5 or above were 23, 24 and
18 years for non-smokers, ex-smokers and current smokers from
the disease onset, respectively. Median times to MSSS score cat-
egory 7.5 or above were 39, 39 and 26 years for non-smokers,
ex-smokers and current smokers from the disease onset, respect-
ively (Fig. 1). Current smokers reached MSSS score categories 45
and 47.5 in a significantly shorter time compared with never-
smokers [hazard ratio (HR) = 1.63, P50.001, 95%CI: 1.32–2.01
and HR = 1.98, P5 0.001, 95%CI: 1.43–2.75, respectively). There
were no differences in the risk of reaching MSSS score categories
45 and 47.5 between ex-smokers and non-smokers. The aver-
age MSSS was higher by 0.68 (P = 0.001, 95%CI: 0.36–1.01) for
ever-smokers compared with never-smokers while controlling for
sex, onset age, initial multiple sclerosis type and use of disease
modifying treatment using linear regression model.
Time to Expanded Disability Status
Scale scores 4 and 6
The time to EDSS score 4 was unavailable in 71 patients (8%), and
time to EDSS score 6 was unavailable in 29 patients (3.2%). The
results of the survival summary and the Cox proportional hazard
regression model are listed in Table 2. The final models were ad-
justed for onset age, use of disease modifying treatment and stra-
tified by sex and/or disease initial type to hold the proportionality
assumption. There was a significant difference in time to EDSS 4
and 6 between ever-smokers and never-smokers. Ever-smokers
were 1.34 (P = 0.001, 95%CI: 1.12 to 1.60) and 1.25 (P = 0.02,
95%CI: 1.02 to 1.51) times more likely than never-smokers to











reach EDSS scores 4 and 6, respectively (Fig. 2). A higher risk of
reaching EDSS scores 4 and 6 was found for current smokers
compared with non-smokers. Ex-smokers had a significantly
lower risk of reaching EDSS scores 4 (HR: 0.65, 95%CI:
0.50–0.83) and 6 (HR: 0.69, 95%CI: 0.53–0.90) than current
smokers. There were also no significant differences in the time
to EDSS scores 4 and 6 between patients who stopped smoking
before multiple sclerosis onset and those who stopped after
developing multiple sclerosis.
Daily cigarette consumption and
disability progression
Average daily cigarette use was available for 807 individuals
[mean (SD) 6.6 (9.5) cigarettes per day, range 0 to 60]. We
examined the effects of daily cigarette use on the MSSS score. We
observed that the average MSSS is increased by 0.04 (P50.001,
95%CI: 0.02 to 0.06) for each extra cigarette consumed per day.
This means that an increase in the number of cigarettes smoked
daily at the time of disease onset or diagnosis by 10 was asso-
ciated with an increase in the MSSS of 0.4 at an average of 16
years later.
Discussion
In this study, we found that disease progression is more rapid
amongst ever-smokers. Ever-smoking in our cohort was associated
with a significant increase in both of the clinical outcomes (MSSS
and EDSS score). Here we present, to our knowledge for the first
time, evidence of the potential beneficial effects of smoking ces-
sation on disability progression in patients with multiple sclerosis.
We found that ex-smokers have a significantly reduced risk of
reaching EDSS score milestones 4 and 6 compared with current
smokers, and that this risk reduction was similar between those
who stopped smoking before or after the onset of multiple scler-
osis. Thus, there are positive effects of smoking cessation on dis-
ease progression even after multiple sclerosis onset. Our study
provides new, important clinical findings on the influence of to-
bacco use in a cohort of patients with multiple sclerosis. We used
a population of patients with multiple sclerosis, all with clinically
definite multiple sclerosis confirmed by multiple sclerosis specialist
neurologists. Most importantly, our clinic and consequently
our cohort, has a population-based nature as it is estimated
to cover 498% of the patients with multiple sclerosis in
Nottinghamshire and defined parts of Lincolnshire and
Derbyshire regions. Our findings are based on diagnosis, identifi-
cation and classification of patients and like any other study may
be subject to bias in ascertainment, recruitment and misclassifica-
tion of status. However, the fact that the confirmation of the
diagnosis and the disability scores in our study were obtained
from a clinical database of multiple sclerosis specialist neurologists
increases the homogeneity and integrity of our results. Thus, our
findings are robust, and characteristics such as gender distribution,
age of onset and type of multiple sclerosis distribution of our
cohort are similar to those reported in most other multiple sclerosis
cohorts. Thus our sample population appears to be representative
Figure 1 Kaplan–Meier survival graph showing times to MSSS
score 45 (A) and MSSS score 7.54 (B) by ever-smokers versus
never-smokers from the disease onset.






Age* (mean, SD) 49.98 (10.92) 48.53 (11.03)
Sex (female) 348 (77.16%) 277 (62.39%)
EDSS† (median, IQR) 5.5 (3.5) 6 (3)
MSSS (mean, SD) 5.13 (2.70) 5.93 (2.52)
Disease duration
(mean, SD)
17.70 (10.15) 15.89 (9.51)
Age at the onset
(mean, SD)
32.29 (9.97) 32.75 (9.70)
Type of the disease
Relapsing-remitting 226 (50.11%) 217 (48.87%)
Primary-progressive 51 (11.31%) 51 (11.49%)
Secondary-progressive 174 (38.58%) 176 (39.64%)
Disease modifying
treatment 51 year
173 (38.36%) 183 (41.22%)
*Age at the last clinic visit.
†EDSS recorded at the last clinic visit.











of the multiple sclerosis population at large and our findings can
be generalized and are reflective of routine clinical practice. Our
study has some limitations that may have influenced our esti-
mates. It is likely that our cohort missed some patients with very
severe disease who died before attending our multiple sclerosis
clinic. We assessed the potential impact of this survivorship bias
on our results by estimating changes in odds ratios or coefficients
while adding patients with longer disease duration to the models
(data not shown). The effects of smoking on the disease progres-
sion of these patients were similar to that of the whole cohort.
We believe our study is one of the most comprehensive studies
to examine the correlation of tobacco smoking and multiple scler-
osis clinical outcomes, with particular emphasis on disability pro-
gression. In a study of a UK population, Hernan et al. (2005)
found a risk ratio of 3.6 years (95%CI: 1.3–9.9) for transition to
secondary-progressive multiple sclerosis in 179 cases of multiple
sclerosis with median 5.3 years follow-up using the General
Practice Research Database. In our study we estimated the risk
of reaching EDSS score 6, which is a robust outcome measure
and a surrogate of time to secondary-progressive multiple sclerosis
(Scalfari et al., 2010) and also allows inclusion of primary-progres-
sive multiple sclerosis. Using these outcomes we found a higher
risk ratio of reaching EDSS score 6 in smokers, although the risk
ratio was lower than the risk ratio reported by Hernan et al.
(2005) for development of secondary-progressive multiple scler-
osis. Although the, risk ratios were in the same direction, differ-
ences in patient sample size [895 in our study versus 179 in the
Hernan et al. (2005) study], longer duration of follow-up (15
versus 5.3 years), and number of patients reaching the outcome
(450 versus 20) may account for the difference in risk ratios.
Others have also used time to EDSS 4 and 6, however with no
significant evidence of association between cigarette smoking and
progression (Koch et al., 2007). We believe that greater sample
size and longer duration of follow-up makes our estimates more
robust. Our results are in accordance with the results from an
observation by D’hooghe et al. (2012), which showed higher
risk of reaching EDSS score 6 amongst occasional and daily cigar-
ette consumers. D’hooghe et al. (2012) relied on questionnaires
for obtaining data on disease onset and self-reported disability
scores that may introduce some bias. The advantage of our
study is its higher homogeneity in terms of clinical data used
such as disease type and EDSS scores that were based on face-
to-face patient examination and recorded by multiple sclerosis
Figure 2 Kaplan–Meier survival graph showing times to EDSS
score 4 (A) and EDSS score 6 (B) by ever-smokers versus never-
smokers from the disease onset.
Table 2 Kaplan–Meier estimates of the time to EDSS scores 4 and 6 and the results of Cox hazard regression model by
smoking status
Smoking status n Median time to EDSS 4
from onset (95%CI)
Median time to EDSS
4 from birth (95%CI)
Hazard ratio (95%CI)
Non-smokers 417 16 (14–19) 50 (48–51) Reference
Stopped before onset 58 11 (9–18) 52 (47–58) 1.01 (0.7–1.46)
Stopped after onset 107 18 (14–20) 50 (47–52) 1.03 (0.8–1.34)
Current smokers 231 11 (9–12) 45 (42–47) 1.64 (1.33–2.02)
n Median time to EDSS 6
from onset (95%CI)
Median time to EDSS
6 from birth (95%CI)
Hazard ratio (95%CI)
Non-smokers 439 22 (19–25) 54 (53–55) Reference
Stopped before onset 64 15 (10–19) 56 (50–60) 0.97 (0.66–1.4)
Stopped after onset 111 23 (20–25) 54 (51–55) 1.04 (0.78–1.38)
Current smokers 241 16 (13–20) 50 (47–53) 1.49 (1.18–1.86)











specialist neurologists. By comparing the two lower and upper
MSSS quartiles we showed that smokers are more likely to have
a severe disease course as shown previously (Gholipour et al.,
2011). A higher probability of progressive onset amongst smokers
has been observed previously (Sundstrom and Nystrom, 2008;
Healy et al., 2009); however, our estimate in a much larger
sample showed no evidence that smoking favours a progressive
onset of the disease.
Smoking is known to be a significant risk factor for the devel-
opment and progression of several autoimmune diseases (Prummel
and Wiersinga, 1993; Saag et al., 1997; Hardy et al., 1998;
Hudson et al., 2011) and is a frequently studied health behaviour
because of its well-known associations with chronic diseases.
Because disease progression is more rapid in ever-smokers, pre-
venting smoking may be important in reducing the progression of
multiple sclerosis. Estimating the impact of smoking in terms of
costs shows its relevance. Costs of multiple sclerosis (direct and
indirect) can increase by nearly 2-fold in patients with EDSS score
3.5 to 6 compared with those with EDSS score 43, from £7273 to
£12 875 per patient per year (Kobelt et al., 2006). In the UK, it
has been estimated that each quality adjusted life year gained in
multiple sclerosis by means of disease modifying treatments costs
from £18 700 to £25 500 (Gani et al., 2008). Based on our results
and compared to these figures, preventing or stopping smoking
could be an economical strategy and an effective way to improve
outcomes in multiple sclerosis that can be implemented along
other multiple sclerosis therapeutic approaches.
It is not clear whether this additional increase in impairment
and disability in ever-smokers is purely due to the biological
influence of tobacco smoking on multiple sclerosis specifically,
or is due to other underlying factors such as increase in comor-
bidities associated with smoking. It has been previously reported
that smokers with multiple sclerosis are more likely to report
comorbid autoimmune diseases (Marrie et al., 2011). Although
comorbidity may account for parts of the progression seen in
ever-smokers, there are lines of evidence that suggest a potential
pathophysiological role of tobacco smoke on the progression of
the disease in multiple sclerosis. Of note, findings from MRI
studies, evidence on the negative impact of smoked tobacco
but not moist snuff on risk of multiple sclerosis as demonstrated
by Hedstrom et al. (2009) as well as a significant association
between smoking intensity and disease severity (dose-response
rate) as demonstrated in our study may suggest a direct
impact of tobacco smoke on multiple sclerosis progression.
Nevertheless the possibility of an indirect impact of smoking
on multiple sclerosis progression, or a combination of direct
and indirect effects cannot be excluded.
There are some likely biological explanations for a mechanistic
pathway between smoking and disability accumulation in multiple
sclerosis (Pryor et al., 1998; Bijl et al., 2001; Malkawi et al.,
2009). Exposure to tobacco smoke has been shown to alter the
innate and adaptive immune cells (Holt and Keast, 1977).
Increased risk of cancer, cardiovascular and other chronic diseases
amongst smokers may possibly be related to smoking-induced
changes in the immune system. Further work is needed to eluci-
date the mechanism by which smoking increases the risk of pro-
gression in multiple sclerosis.
Conclusions and implications
In summary, we found that ever-smokers with multiple sclerosis
accumulate more disability over a shorter period of time and suffer
from more severe disease than never-smokers. Our findings point
toward the beneficial effect of smoking cessation even after the
disease onset in patients with multiple sclerosis. Measures to
prevent and reduce smoking may lead to improved outcomes in
multiple sclerosis.
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